Shenzhen Duoyi Technology Co. LTD – Trademark Portfolio

Entity Type: 99

Shenzhen Duoyi Technology Co. LTD holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. Currently, 1 trademark is registered and 1 is pending. Notable registered marks include YIMIDUK. The owner is based in Longhua Dist, Shenzhen.

A601, Unit A.B.C, Hepeng Yuan, Shuidou

Laowei Vil,Yousong Community,Longhua St

Longhua Dist, Shenzhen 518110 , CN

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

YIMIDUK
YIMIDUK
Registered 2024
YIMIDUK
YIMIDUK
Pending 2022

Trademark Classifications

Shenzhen Duoyi Technology Co. LTD's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Shenzhen Duoyi Technology Co. LTD have?

Shenzhen Duoyi Technology Co. LTD has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 pending.

What trademark classes does Shenzhen Duoyi Technology Co. LTD file in?

Shenzhen Duoyi Technology Co. LTD files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Shenzhen Duoyi Technology Co. LTD's most well-known trademarks?

Shenzhen Duoyi Technology Co. LTD's registered trademark portfolio includes well-known marks such as YIMIDUK. These are among 1 currently registered trademark in the portfolio.

What is Shenzhen Duoyi Technology Co. LTD's trademark registration success rate?

Shenzhen Duoyi Technology Co. LTD has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 1 application is pending review.